ScreenerHero
PHRPharmena S.A.Partial data
GPW · PL · Healthcare · Biotechnology · pharmena.eu
3.120PLN+1.63%Mkt Cap: 8.80M $P/E: —

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap8.80M $
Enterprise Value8.75M $
Revenue (TTM)406.48K $
Gross Profit332.53K $
Net Income (TTM)-701.28K $
Revenue/Share0.0365 USD
Last Price3.120 PLN
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLPHRMN00011
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-11.02
EV/Revenue21.54
P/S21.65
P/B3.79
EPS (TTM)-0.25
EPS (Forward)—
52W Range
2.50034% of range4.320
52W High4.320 PLN
52W Low2.500 PLN
Profitability
Gross Margin83.26%
Oper. Margin-131.12%
EBITDA Margin-195.45%
Profit Margin-175.59%
ROE-28.70%
ROA-25.35%
Growth
Revenue Growth7.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-833.23K $
CapEx (TTM)1.92M $
FCF Margin28.75%
FCF Yield1.33%
Net Debt-17.98K $
Net Debt/EBITDA0.02
Balance Sheet
Debt/Equity0.04
Current Ratio9.64
Quick Ratio1.16
Book Value/Sh0.8230 PLN
Cash/Share0.0370 PLN
Dividends
Fwd Div Rate2.360 PLN
Trail. Div Rate0.0000 PLN
Div. Yield74.92%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateSep 10, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.11.14M
Float3.31M
Insiders70.30%
Institutions1.86%
Technical
SMA 503.140 (-0.6%)
SMA 2003.289 (-5.1%)
Beta0.50
S&P 52W Chg19.97%
Avg Vol (30d)2.00K
Avg Vol (10d)4.47K
Technical Indicators
RSI (14)44.3
MACD-0.0452
MACD Signal-0.0436
MACD Hist.-0.0016
BB Upper3.265 PLN
BB Middle3.163 PLN
BB Lower3.061 PLN
BB Width6.45%
ATR (14)0.1004 PLN
Vol Ratio (20d)1.72x